CMS In Brief

Latest news from the Medicare agency includes updates from the physician fee schedule and clinical laboratory fee schedule, an American Hospital Association lawsuit, and more.

In a CMS-commissioned report released Nov. 7, the HHS Office of Inspector General found that suppliers’ improper billing of beneficiaries for non-mail order diabetes test strips contributed to a 33% increase in non-mail order test strip claims in competitive bidding areas from 2010-2011. During the same time period, less expensive mail order supplies were found to have decreased by 71%. OIG discovered that for 20% of the 211 beneficiaries reviewed for the report, suppliers had improperly billed Medicare for the non-mail order diabetes test strips in 2011, whereas beneficiaries reported having received the less expensive mail order test strips. In addition, 23% of beneficiaries reviewed by OIG reported supplier activities – such as waiving their co-payments and sending them unsolicited testing supplies – that OIG determined to be inappropriate. While OIG made no recommendations in the report, it noted that this information could be useful to CMS as the agency prepares to implement the national mail order competition for diabetes suppliers as part of it its durable medical equipment, prosthetics/orthotics and supplies competitive bidding program, projected to begin in 2013.

CMS released estimated payment rates for three new Category 1 CPT codes – totaling $833 in aggregate – related to procedures using Abiomed Inc.’s Impella heart pump, the company...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Policy & Regulation

FDA Rebukes Four Companies, Including One Overseas, For Procedural Failures

 

The US FDA’s device center sent warning letters to three domestic device manufacturers and one German firm for failing to adhere to protocol on several issues.

EU Finalizes Framework For Joint Clinical Assessments Of High-Risk Devices

 

Second submission window for joint scientific consultations on a procedure to help prepare for joint clinical assessments will open from 2 to 30 June 2025.

Get Ready For International Harmonization Before Approaching QMSR Deadline, Says Regulatory Expert

 

During MD&M East last week, regulatory consultant Darren Reeves reminded device manufacturers that the time to get ready to comply with the new Quality Management System Regulation is now.

UK Take Care! Regulatory And Market Access Reforms Must Not Shut Out Medtech Growth

 
• By 

Speakers at a recent UK medtech outlook conference voiced optimism about the sector’s prospects, but warned that cost burdens, over-regulation and lengthy processes will impede the capacity of local SMEs to innovate. Only 10% of NHS procured medtech comes from UK manufacturers.

More from Medtech Insight

Get Ready For International Harmonization Before Approaching QMSR Deadline, Says Regulatory Expert

 

During MD&M East last week, regulatory consultant Darren Reeves reminded device manufacturers that the time to get ready to comply with the new Quality Management System Regulation is now.

Handheld Diagnostics: A Resurging Category That is Here to Stay

 

Handheld diagnostics are more powerful, accessible and clinically relevant than ever. Medtech Insight spoke to companies behind such technologies to learn how they work and discuss their commercial models.

Execs On The Move: 12-23 May 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.